Comparative neuroprotective effects of methylprednisolone and rosiglitazone, a peroxisome proliferator-activated receptor-γ following spinal cord injury.
To compare the neuroprotective effects of methylprednisolone (MPSS) and rosiglitazone (ROSG) following spinal cord injury (SCI). This study was carried out at the Institute of Orthopedics, the First Affiliated Hospital of Soochow University, Suzhou, China between June 2009 and March 2010. One hundred and twenty Sprague-Dawley rats after SCI were divided into 4 different groups (30/group): i) SCI-vehicle group, ii) MPSS group, iii) ROSG group, and iv) sham saline group. The following 5 aspects were evaluated: 1) spinal cord inflammation and tissue injury; 2) neutrophil infiltration; 3) cell apoptosis; 4) the expression of proinflammatory cytokines tumor necrosis factor-α and interleukin-β; and 5) the expression of tissue Bax, Bcl-2, and HSP70 proteins in situ. Notably, ROSG showed similar neuroprotective effects to MPSS, and significantly decreased spinal cord damage, apoptosis, and cytokine expression. There were no significant differences between the MPSS or ROSG-treated groups. Administration of ROSG after SCI reduces the development of inflammation and tissue injury associated with spinal cord trauma.